Outcomes for patients who are diagnosed with breast and endometrial cancer

Martin-Dunlap, Tonya M.; Wachtel, Mitchell S.; Margenthaler, Julie A.

doi:10.3892/ol.2013.1491

Cited by 7 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Singh et al reported that physical inactivity may influence the cancer mortality and incidence [ 58 , 59 ]. The reproductive factors were mainly related to the breast, ovarian, and endometrial cancer [ 60 , 61 ]. In addition, except for controlling the risk factors, the earlier diagnosis of cancer and optimal treatment may have an important role on cancer survival.…”

Section: Discussionmentioning

confidence: 99%

All-Cause and Cancer Mortality Trends in Macheng, China (1984–2013): An Age-Period-Cohort Analysis

2018

IJERPH

View full text Add to dashboard Cite

The aim was to study the variation trends of all-cause and cancer mortality during 1984–2013 in Macheng City, China. The mortality data were collected from Macheng City disease surveillance points system and Hubei Center for Disease Control and Prevention. The model life table system was used to adjust mortality rates due to an under-reporting problem. An age-period-cohort model and intrinsic estimator algorithm were used to estimate the age effect, period effect, and cohort effect of all-cause mortality and cancer mortality for males and females. Age effect of all-cause mortality for both sexes increased with age, while the age effect of cancer mortality for both sexes reached a peak at the age group of 55–59 years old and then decreased. The relative risks (RRs) of all-cause mortality for males and females declined with the period and decreased by 51.13% and 63.27% during the whole study period, respectively. Furthermore, the period effect of cancer mortality in both sexes decreased at first and then increased. The cohort effect of all-cause and cancer mortality for both sexes born after 1904 presented the pattern of “rise first and then fall,” and decreased by 82.18% and 90.77% from cohort 1904–1908 to 1989–1993, respectively; especially, the risk of all-cause and cancer mortality for both sexes born before 1949 was much higher than that for those born after 1949.

show abstract

Section: Discussionmentioning

confidence: 99%

All-Cause and Cancer Mortality Trends in Macheng, China (1984–2013): An Age-Period-Cohort Analysis

2018

IJERPH

View full text Add to dashboard Cite

show abstract

“…There were 59 women (41.8%) who were given a diagnosis of BC first versus 82 (58.2%) with EC first; this was in contrast to 63.9% who were given a diagnosis of BC first in the larger observational study using the SEER database. 17 That study also showed a 45-month median between cancer diagnoses but however did not specifically divide patients into the 2 groups that we have done in this study. Here, the time interval between the 2 diagnoses was found to be similar among women in groups 1 and 2.…”

Section: Discussionmentioning

confidence: 84%

“…9 One study used SEER data to evaluate more than 2000 women with history of both BC and EC, and they concluded that the cumulative mortality at 5 years after the second cancer diagnosis was almost 4-fold likely to be due to BC rather than EC. 17 The association of EC after treatment with adjuvant tamoxifen treatment in patients with previous BC is well established. 18 Higher-grade EC was also found to be more common in this population.…”

Section: Discussionmentioning

confidence: 99%

“…These findings are compatible with the SEER database study, where it was demonstrated that the risk of death from EC was markedly lower if the original malignancy was EC. 17 Those authors hypothesized that the women in the SEER database with BC first would likely have received tamoxifen and thus would have been at risk for developing higher-grade ECs. 25 Despite the potential higher grade, however, in a study of 163 women who had BC followed by EC, EC survival was comparable in both tamoxifen and nontamoxifen users.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use

Grzankowski

Szender

Spring-Robinson

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

Background The time interval between diagnoses of breast cancer (BC) and endometrial cancer (EC) is not well established in women with metachronous primary tumors. We sought to examine this interval and identify associations with treatment-related and clinicopathologic factors. Methods We identified 141 patients who developed both cancers during 1966 to 2013. Patients were divided into 2 groups: group 1, BC first, and group 2, EC first. Subanalysis performed of group 1 (59 patients) stratified around adjuvant tamoxifen use: pre-1990 BC diagnosis and post. Results Fifty-nine and 82 patients were in groups 1 and 2, respectively. The mean time interval was comparable (76 vs 74 months, P = 0.861). Subanalysis divided group 1 into pre- (n = 27) and post- (n = 32) 1990 and resulted in different mean time intervals between diagnosis of metachronous cancers (106 vs 50 months, respectively [P = 0.042]). Median progression-free survival (PFS) and overall survival (OS) for EC were longer in the pre group (PFS, 51 vs 26 months [P = 0.169]; OS, 59 vs 27 months [P = 0.190]). Median PFS and OS for BC were also longer in this group (PFS, 147 vs 109 months [P = 0.005]; OS, 166 vs 114 months [P < 0.001]). Conclusions Our data indicate the mean time interval between the diagnosis of EC and BC was approximately 6 years. Disease-specific EC survival was worse for patients with a previous diagnosis of BC. Stratification around implementation of tamoxifen use shows comparable grade and stage but different time interval and survival, suggesting resulting effects from adjuvant therapy for BC. These results are useful in counseling women at risk.

show abstract

“…Only a few studies have evaluated the long-term outcomes, including the development of second cancer, in en- dometrial cancer survivors [11][12][13][14][15][16][17][18][19][20]. However, none compared second cancer rate between premenopausal and postmenopausal survivors.…”

Section: Discussionmentioning

confidence: 99%

Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis

2020

EJGO

View full text Add to dashboard Cite

The aim of this study was to assess risk factors associated with developing second cancer in premenopausal and postmenopausal endometrial cancer survivors using data from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate analysis revealed that for both groups age was a risk factor for second cancer development. For premenopausal women, being white versus black, having endometrioid adenocarcinoma compared with other histological types increased the risk of developing a second cancer (p values ≤ 0.018). For postmenopausal women, being Non-Spanish-Hispanic-Latino versus Spanish-Hispanic-Latino, having squamous cell carcinoma versus endometroid adenocarcinoma, N0 compared with N1 nodes, M0 versus M1 metastasis, and no surgery or radiotherapy compared with surgery alone or surgery plus radiotherapy increased the likelihood of developing second cancer (p values ≤ 0.012). The results of Cox proportional hazard analysis indicated that premenopausal and postmenopausal women with endometrial cancer who underwent surgery plus radiotherapy showed the greatest benefit with respect to cause-specific survival (adjusted HR 0.192, 95%CI: 0.135 to 0.274, and adjusted HR 0.206, 95%CI, 0.184 to 0.230, respectively). In summary, risk factors for second cancer in survivors of endometrial cancer differ between premenopausal and postmenopausal women, and suggests that the two groups of women should be managed differently.

show abstract

Outcomes for patients who are diagnosed with breast and endometrial cancer

Cited by 7 publications

References 11 publications

All-Cause and Cancer Mortality Trends in Macheng, China (1984–2013): An Age-Period-Cohort Analysis

All-Cause and Cancer Mortality Trends in Macheng, China (1984–2013): An Age-Period-Cohort Analysis

Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use

Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis

Contact Info

Product

Resources

About